Aurinia Pharmaceuticals Inc. (AUPH)
5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms
Innovation is at its peak for the Zacks Medical-Drugs industry. AUPH, HRTX, ESPR, PYXS and PSTV may prove to be good additions to one's portfolio.
Insiders Are Loading Up on These 4 Biotech Stocks Now
Things are heating up in the biotechnology space, with a flurry of recent initial public offerings and some notable insider purchases of the past week or so.
Autoimmune Disease-Focused Aurinia Pharmaceuticals Reports Quarterly Profit, Revenue Outlook Below Expectations
On Thursday, Aurinia Pharmaceuticals Inc AUPH reported fourth-quarter earnings of 1 cent per share, compared to a loss of 19 cents a year ago and the consensus loss of 2 cents.
Aurinia Pharmaceuticals Inc. (AUPH) Q4 2024 Earnings Call Transcript
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Andrea Christopher - Head, Corporate Communications and Investor Relations Peter Greenleaf - President, Chief Executive Officer and Director Joe Miller - Chief Financial Officer Greg Keenan - Chief Medical Officer Conference Call Participants Vishwesh Shah - TD Cowen Olivia Brayer - Cantor Fitzgerald Farzin Haque - Jefferies Will Soghikian - Leerink Partners Ed Arce - H.C. Wainwright Operator Greetings, and welcome to the Aurinia Pharmaceuticals Fourth Quarter and Full-Year 2024 Earnings Call.
Aurinia Pharmaceuticals (AUPH) Beats Q4 Earnings and Revenue Estimates
Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.09 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to loss of $0.19 per share a year ago.
Aurinia Pharmaceuticals: There's Still Time For Sales Growth
AUPH's Lupkynis showed modest revenue growth from Q2'24 to Q3'24, but limited sales growth going from Q2 to Q3 has been seen previously. Full-year 2024 net product revenue guidance of $210M-$220M appears achievable, with $158.6M already reported and Q4 typically outperforming Q3. Potential competitors in lupus nephritis and even in systemic lupus erythematosus include Roche and Biogen.
Aurinia (AUPH) Upgraded to Buy: Here's Why
Aurinia (AUPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
3 Biotech Stocks With Notable Insider Buying
Small biotech stocks have struggled recently, with the SPDR® S&P Biotech ETF down over 15% in the past ten weeks. The pullback has presented significantly lower entry points on myriad small and mid-cap biotech and biopharma stocks. Today, we look at three of these names that have seen notable recent purchases from insiders and/or beneficial owners.
Aurinia Pharmaceuticals: A Potential Buyout Looms On The Horizon
Today, we are following up on biopharma name Aurinia Pharmaceuticals Inc. The company just posted solid Q3 results this week and announced significant cost reduction measures. Aurinia is seeing impressive sales growth, has a pristine balance sheet and should become increasingly profitable in coming years.
Aurinia Pharmaceuticals, Inc. (AUPH) Q3 2024 Earnings Call Transcript
Aurinia Pharmaceuticals, Inc. (NASDAQ:AUPH ) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Andrea Christopher - Head, Corporate Communications & IR Peter Greenleaf - President, CEO & Director Greg Keenan - Chief Medical Officer Joe Miller - CFO Conference Call Participants Stacy Ku - TD Cowen Maurice Raycroft - Jefferies Olivia Brayer - Cantor Fitzgerald Will Soghikian - Leerink Partners Operator Greetings, and welcome to Aurinia Pharmaceuticals Third Quarter 2024 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded.
Aurinia Pharmaceuticals (AUPH) Q3 Earnings and Revenues Beat Estimates
Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.09 per share a year ago.
3 Small Biotech Stocks With The 'Big Mo' Right Now
Three small biotech stocks that I have covered lately have shown significant upward movement recently due to positive news. The stocks are experiencing what I call the 'Big Mo,' indicating strong momentum that could lead to additional upward movement. We follow up on these three small biotech/biopharma names and bring followers up to date on the recent positive news flow around them in the paragraphs below.
